Literature DB >> 16540545

Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.

L Brulhart, A Ciurea, A Finckh, A Notter, J M Waldburger, D Kyburz, C Gabay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16540545      PMCID： PMC1798288          DOI： 10.1136/ard.2005.051169

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

Review 1.  B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

Authors:  T Shaw; J Quan; M C Totoritis
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 2.  Prospects for B-cell-targeted therapy in autoimmune disease.

Authors:  J C W Edwards; G Cambridge
Journal:  Rheumatology (Oxford)       Date:  2004-10-27       Impact factor: 7.580

3.  Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis.

Authors:  Esther Jimenez-Boj; Kurt Redlich; Birgit Türk; Beatrice Hanslik-Schnabel; Axel Wanivenhaus; Andreas Chott; Josef S Smolen; Georg Schett
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

Review 4.  Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.

Authors:  Lisa G Criscione; E William St Clair
Journal:  Curr Opin Rheumatol       Date:  2002-05       Impact factor: 5.006

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

7.  Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria.

Authors:  J Fransen; M C W Creemers; P L C M Van Riel
Journal:  Rheumatology (Oxford)       Date:  2004-07-06       Impact factor: 7.580

8.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

Authors:  A M van Gestel; M L Prevoo; M A van 't Hof; M H van Rijswijk; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1996-01

9.  Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.

Authors:  A M van Gestel; C J Haagsma; P L van Riel
Journal:  Arthritis Rheum       Date:  1998-10
  9 in total
  10 in total

1.  Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.

Authors:  Mattias Magnusson; Mikael Brisslert; Kiandoht Zendjanchi; Magnus Lindh; Maria I Bokarewa
Journal:  Rheumatology (Oxford)       Date:  2010-06-14       Impact factor: 7.580

2.  B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra. Good responses in an extreme negative selection.

Authors:  J C Henes; C Richter; L Kanz; I Koetter
Journal:  Rheumatol Int       Date:  2007-06-12       Impact factor: 2.631

3.  Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis.

Authors:  Koji Takasugi; Masahiro Yamamura; Mitsuhiro Iwahashi; Fumio Otsuka; Jiro Yamana; Katsue Sunahori; Masanori Kawashima; Masao Yamada; Hirofumi Makino
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

4.  Characterization of antigen-specific B cells using nominal antigen-coated flow-beads.

Authors:  Nicolas Degauque; Annie Elong Ngono; Annie Elong Ngono; Ahmed Akl; Maud Lepetit; Romain Crochette; Magali Giral; Julie Lepourry; Annaick Pallier; Stéphanie Castagnet; Emilie Dugast; Cécile Guillot-Gueguen; Marylène Jacq-Foucher; Xavier Saulquin; Anne Cesbron; David Laplaud; Arnaud Nicot; Sophie Brouard; Jean-Paul Soulillou
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

Review 5.  Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics.

Authors:  Fabrizio Cantini; Carlotta Nannini; Laura Niccoli; Linda Petrone; Giuseppe Ippolito; Delia Goletti
Journal:  Mediators Inflamm       Date:  2017-06-01       Impact factor: 4.711

6.  Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review.

Authors:  Hema Chaplin; Lewis Carpenter; Anni Raz; Elena Nikiphorou; Heidi Lempp; Sam Norton
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

7.  Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.

Authors:  Maria Rehnberg; Sylvie Amu; Andrej Tarkowski; Maria I Bokarewa; Mikael Brisslert
Journal:  Arthritis Res Ther       Date:  2009-08-17       Impact factor: 5.156

8.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06

9.  Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice.

Authors:  Amrita Srivastava; Britni M Arlian; Lijuan Pang; Takashi K Kishimoto; James C Paulson
Journal:  ACS Chem Biol       Date:  2021-05-26       Impact factor: 4.634

10.  Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective study.

Authors:  Ling Yin Ho; Chi Chiu Mok; Chi Hung To; Mak Anselm; Mei Yuk Cheung; Ka Lung Yu
Journal:  Open Rheumatol J       Date:  2007-09-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.